Center for Personalized Diagnostics

Overview

Penn Medicine's Center for Personalized Diagnostics (CPD) is a clinical genomics laboratory established in 2013 through a collaboration between Penn’s Cancer Center and the Department of Pathology and Laboratory Medicine. The CPD utilizes massively parallel sequencing to analyze variations in genes related to solid and hematologic malignancies, allowing for simultaneous evaluation of multiple genes in a cancer specimen. The CPD aims to uncover genetic mutations within a patient's cancer to facilitate a targeted and personalized "precision" treatment strategy. CPD testing assists the clinical oncology teams at Penn Medicine, by providing information to identify individualized therapies that can dramatically alter a patient's treatment course and outcome.

The laboratory is led by doctoral level faculty with specialty training and board certification in molecular genetic diagnostics and genomics. Expert staff consisting of Genomic Laboratory Technologists, Bioinformatics Scientists, and Genomic Variant Analysts partner with faculty to provide high quality testing for patients. The CPD provides education support to various learners including residents, fellows, and medical laboratory science students by offering rotations and other educational opportunities.

For more information see Guide to Laboratory Services (HUP Test Menu) or contact Penn Labs Client Services Group directly at 800-PENN-LAB.

Highlights

  • Precision genomic oncology testing is available for therapeutic decision-making, diagnosis, disease monitoring, and risk assessment.
  • PennSeqTM Hematologic Malignancies Panel provides DNA sequence analysis of more than 200 genes associated with hematological malignancies.
  • PennSeqTM Solid Tumor Panel provides DNA sequence analysis of more than 200 genes associated with solid tumors.
  • Penn Precision Panel provides reflex testing for poor quality and/or low quantity DNA specimens, with targeted sequence analysis of a subset of genes from the larger PennSeq Solid panel.
  • Fusion Transcript Panel provides RNA sequence analysis of genes for rearrangements detected in solid tumors. This analysis is partner agnostic, allowing for detection of fusions involving cancer associated genes with a variety of partners.
  • Targeted Expedited Molecular Profiling (TEMP) provides targeted, rapid DNA sequence analysis in parallel with RNA sequence analysis to detect specific gene mutations, fusions, and isoforms associated with select solid tumors.

Current CPD gene panels

Contact

Jennifer J.D. Morrissette, PhD. FACMG
Director, Center for Personalized Diagnostics
JeMorris@pennmedicine.upenn.edu


David Lieberman, MS, CGC, FACHE
Associate Administrative Director
David.Lieberman@pennmedicine.upenn.edu


Center for Personalized Diagnostics Laboratory
Tel: 215-615-3966
Fax: 1-215-898-9817